Nivolumab in renal cell cancer: Indication of added benefit
Wednesday, August 10, 2016 - 23:02
in Health & Medicine
Patients with advanced renal cell cancer have weaker symptoms and side effects and patients with an unfavorable prognosis survive longer using Nivolumab than those receiving the comparator therapy.